The safety profiles of both regimens were generally typical of those observed during treatment with pegylated
interferon and
ribavirin.[5,24] We found, however, that a greater percentage of patients treated with peginterferon alpha-2b plus ribavirin discontinued for safety reasons than did patients treated with peginterferon alpha-2a plus ribavirin. Discontinuations because of nonsafety reasons were comparable.